TY - JOUR T1 - Biomarker-based corticosteroid adjustment in severe asthma: a modified Delphi consensus JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00081-2018 VL - 4 IS - 4 SP - 00081-2018 AU - Nicola E. Gallagher AU - Catherine E. Hanratty AU - Marc Humbert AU - Elisabeth Bel AU - Ratko Djukanovic AU - Valerie Hudson AU - Nile Amos AU - Liam G. Heaney A2 - , Y1 - 2018/10/01 UR - http://openres.ersjournals.com/content/4/4/00081-2018.abstract N2 - Asthma is managed using “step-wise” adjustment of corticosteroid therapy to achieve asthma control. When corticosteroid treatment is adjusted using sputum eosinophil count or exhaled nitric oxide fraction, exacerbations are reduced [1, 2]; however, implementation in clinical care has been slow. In parallel, airway transcriptomic analysis has demonstrated that type 2 eosinophilic inflammation is absent in many patients with minimal response to corticosteroid treatment [3–5]. The UK Refractory Asthma Stratification Programme (RASP-UK) (http://rasp.org.uk/) is exploring non-sputum biomarker-based strategies to target corticosteroid treatment in severe asthma [6, 7], and sought to determine clinician and patient views on clinically relevant reductions in corticosteroid treatment.UK asthma physicians are supportive of biomarker-based steroid adjustment, but European physicians need more evidence http://ow.ly/sTrf30my3jwWe would like to thank the physicians in both the UK and European Respiratory Society Severe Asthma Clinical Research Collaboration and the all the patients who took part in the modified Delphi process. ER -